Analysts' ratings for Hims & Hers Health HIMS over the last quarter vary from bullish to bearish, as provided by 6 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 4 | 0 | 2 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 1 | 0 | 0 | 0 | 0 |
2M Ago | 2 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 2 | 0 | 0 |
Analysts have recently evaluated Hims & Hers Health and provided 12-month price targets. The average target is $22.17, accompanied by a high estimate of $25.00 and a low estimate of $18.00. This upward trend is apparent, with the current average reflecting a 9.75% increase from the previous average price target of $20.20.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive Hims & Hers Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Michael Cherny | B of A Securities | Raises | Buy | $25.00 | $23.00 |
Michael Cherny | B of A Securities | Raises | Buy | $23.00 | $20.00 |
Michael Cherny | B of A Securities | Lowers | Buy | $20.00 | $24.00 |
Ryan MacDonald | Needham | Announces | Buy | $24.00 | - |
George Hill | Deutsche Bank | Raises | Hold | $23.00 | $16.00 |
Korinne Wolfmeyer | Piper Sandler | Maintains | Neutral | $18.00 | $18.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hims & Hers Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Hims & Hers Health compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Hims & Hers Health's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Hims & Hers Health's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Hims & Hers Health analyst ratings.
All You Need to Know About Hims & Hers Health
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Hims & Hers Health's Financial Performance
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Hims & Hers Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 51.82% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Hims & Hers Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.21% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.76%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Hims & Hers Health's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.86%, the company showcases efficient use of assets and strong financial health.
Debt Management: Hims & Hers Health's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Understanding the Relevance of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.